Using the Johnson & Johnson vaccine as a booster for people initially immunized with the Pfizer/BioNTech vaccine produces a strong immune response and may do more to elicit protection against severe disease, researchers reported.
Their small study of 65 volunteers who all initially got two doses of Pfizer/BioNTech's vaccine showed that using the J&J Janssen vaccine as a booster produced a slower but more sustained antibody response against the original strain of the virus, as well as the Delta and Beta variants, they said.The vast majority of Republicans don't want a boosterThe Pfizer/BioNTech booster produced a quicker and stronger immune response that dropped off faster, their study suggested.
Read MoreAll vaccinated adults should get a Covid-19 booster shot because of the Omicron variant, CDC saysAntibodies are a first line of immune protection that can stop a virus from ever infecting cells, while T cells come in later and destroy infected cells. This T-cell defense doesn't prevent mild infections, but can stop them from progressing to severe disease.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
A new study finds that most COVID-19 boosters strengthen immunity, though there is no winning shotThe first study directly comparing COVID-19 boosters found that most shots improved immune responses in fully vaccinated people.
Read more »
Is the best strategy against omicron to boost with the original vaccine?Omicron variant: Do current Covid vaccines and boosters protect against the new variant?
Read more »
Facebook 'failing' to tackle COVID-19 misinformation posted by prominent anti-vaccine group, study claimsFacebook is 'failing' to tackle COVID-19 misinformation posted by prominent anti-vaccine group, a study claims.
Read more »
Australia approves Covid vaccine for children aged 5-11Australia on Sunday cleared the first Covid-19 vaccine for children aged five to 11, with the next stage of its vaccine rollout expected to start in early 2022.
Read more »
U.S. administers 468.5 million doses of COVID-19 vaccines- CDCThose figures are up from the 466,348,132 vaccine doses the CDC said had gone into arms by Dec. 3 out of 580,893,145 doses delivered. The CDC tally includes two-dose vaccines from Moderna and Pfizer/BioNTech,, as well as Johnson & Johnson's one-shot vaccine. About 45.3 million people have received a booster dose of either Pfizer, Moderna or Johnson & Johnson's COVID-19 vaccine.
Read more »